Unknown

Dataset Information

0

Licochalcone A inhibits EGFR signalling and translationally suppresses survivin expression in human cancer cells.


ABSTRACT: Dysfunction of epidermal growth factor receptor (EGFR) signalling plays a critical role in the oncogenesis of non-small-cell lung cancer (NSCLC). Here, we reported the natural product, licochalcone A, exhibited a profound anti-tumour efficacy through directly targeting EGFR signalling. Licochalcone A inhibited in vitro cell growth, colony formation and in vivo tumour growth of either wild-type (WT) or activating mutation EGFR-expressed NSCLC cells. Licochalcone A bound with L858R single-site mutation, exon 19 deletion, L858R/T790M mutation and WT EGFR ex vivo, and impaired EGFR kinase activity both in vitro and in NSCLC cells. The in silico docking study further indicated that licochalcone A interacted with both WT and mutant EGFRs. Moreover, licochalcone A induced apoptosis and decreased survivin protein robustly in NSCLC cells. Mechanistically, we found that treatment with licochalcone A translationally suppressed survivin through inhibiting EGFR downstream kinases ERK1/2 and Akt. Depletion of the translation initiation complex by eIF4E knockdown effectively inhibited survivin expression. In contrast, knockdown of 4E-BP1 showed the opposite effect and dramatically enhanced survivin protein level. Overall, our data indicate that targeting survivin might be an alternative strategy to sensitize EGFR-targeted therapy.

SUBMITTER: Gao F 

PROVIDER: S-EPMC7812290 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Licochalcone A inhibits EGFR signalling and translationally suppresses survivin expression in human cancer cells.

Gao Feng F   Li Ming M   Yu Xinfang X   Liu Wenbin W   Zhou Li L   Li Wei W  

Journal of cellular and molecular medicine 20201127 2


Dysfunction of epidermal growth factor receptor (EGFR) signalling plays a critical role in the oncogenesis of non-small-cell lung cancer (NSCLC). Here, we reported the natural product, licochalcone A, exhibited a profound anti-tumour efficacy through directly targeting EGFR signalling. Licochalcone A inhibited in vitro cell growth, colony formation and in vivo tumour growth of either wild-type (WT) or activating mutation EGFR-expressed NSCLC cells. Licochalcone A bound with L858R single-site mut  ...[more]

Similar Datasets

| S-EPMC8626604 | biostudies-literature
| S-EPMC6815810 | biostudies-literature
| S-EPMC7014326 | biostudies-literature
| S-EPMC3735325 | biostudies-other
| S-EPMC3973552 | biostudies-other
| S-EPMC3966979 | biostudies-literature
| S-EPMC3111753 | biostudies-other
| S-EPMC3243624 | biostudies-literature
| S-EPMC5345631 | biostudies-literature
| S-EPMC4960556 | biostudies-other